Core Insights - The article highlights a significant breakthrough in clinical brain-machine interface technology, specifically for precise tumor boundary localization during surgery, marking the first global clinical trial of its kind [1][2]. Group 1: Technology Development - The clinical trial was conducted by the Aerospace Information Research Institute and the First Affiliated Hospital of Harbin Medical University, utilizing the NeuroDepth microelectrode developed by the Aerospace Institute [1]. - The technology includes a high-throughput neural signal detection device (AIRCAS-128) that synchronously collects and analyzes vast amounts of neural signals, converting raw signals into precise "lesion navigation" data for real-time tumor boundary assessment [1]. Group 2: Clinical Application - This technology overcomes the limitations of traditional neural electrodes, which could only detect signals from the brain's surface and shallow layers, allowing for detection across all brain regions, including deep brain areas [2]. - It can also simultaneously detect chemical signals such as dopamine and glutamate, providing comprehensive data to differentiate between tumor and normal tissue, which is crucial for accurate surgical planning and execution [2].

Core Viewpoint - The successful completion of the clinical trial for a brain-machine interface (BMI) technology developed by the Chinese Academy of Sciences marks a significant breakthrough in the precise localization of brain tumor boundaries during surgery, showcasing the potential for improved surgical outcomes and patient quality of life [3][4][6]. Group 1: Clinical Trial and Technology - The clinical trial involved the use of an implanted microelectrode array for precise tumor boundary localization during surgery, representing the first application of BMI technology in this context globally [3][4]. - The technology includes the NeuroDepth microelectrode and the AIRCAS-128 device, which allows for high-resolution, real-time detection of neural signals, enabling accurate identification of tumor boundaries [6][7]. - The microelectrode can detect neural activity at a spatial resolution of 15 micrometers and can be used throughout the entire brain, overcoming limitations of traditional methods [6][7]. Group 2: Clinical Implications - The BMI technology provides real-time navigation for neurosurgery, potentially increasing the rate of successful tumor removals while preserving healthy brain tissue [4][5]. - The clinical trial demonstrated successful tumor removal in a patient with glioma, leading to improved postoperative outcomes without new neurological deficits [7]. - The technology addresses the need for dynamic intraoperative identification of tumor boundaries, which has been a challenge in neurosurgery [7][8]. Group 3: Future Applications and Development - The Chinese Academy of Sciences plans to expand the application of BMI technology to areas such as sensory restoration for visually and hearing-impaired patients, as well as rehabilitation for stroke and hydrocephalus patients [9]. - The successful trial is seen as a critical step towards the clinical translation and industrialization of BMI technology, with ongoing collaboration expected to enhance technological advancements and clinical applications [8][9].

Core Insights - The clinical trial conducted by the Aerospace Information Innovation Research Institute and Harbin Medical University is the first in the world to apply brain-machine interface technology for precise boundary localization of deep brain tumors during surgery [1][2] - The trial utilized the NeuroDepth microelectrode and the AIRCAS-128 device, enabling real-time detection and analysis of neural signals, which aids in accurate tumor boundary identification [1][2] Group 1 - The clinical trial represents a significant breakthrough in domestically developed implantable clinical brain-machine interface technology [1] - The NeuroDepth microelectrode can detect signals from various brain regions, including deep brain areas, overcoming the limitations of traditional electrodes [1] - The technology allows for simultaneous detection of chemical signals, providing comprehensive data to differentiate between tumor and normal tissue [1] Group 2 - The trial was conducted on a glioma patient who experienced frequent seizures due to tumor pressure, and it successfully identified tumor boundaries while preserving functional areas [2] - The success of this clinical trial marks a critical step towards the clinical translation and industrialization of brain-machine interface technology [2]

记者28日从中国科学院空天信息创新研究院（以下简称"空天院"）获悉，该院传感器技术全国重点实验 室与哈尔滨医科大学附属第一医院联合完成了"基于植入式微电极阵列的脑深部肿瘤边界精准定位"临床 试验。这是全球范围首个脑机接口应用于脑深部肿瘤术中边界精准定位的临床试验，标志着我国自主研 发的植入式临床脑机接口技术实现重要突破。 该临床试验采用了空天院自主研发的临床脑机接口微电极（NeuroDepth），以及多层次调控与高通量神 经信号同步检测仪（AIRCAS-128）。前者通过实时信号检测，高精度获取肿瘤边界特征信号；后者可 同步采集、分析海量神经信号，将电极捕捉的原始信号转化为精准的"病灶导航"，为肿瘤术中边界判断 提供实时数据。 "该技术不仅突破了传统神经电极仅能检测脑表面和浅层的局限，可探测包含脑表面、浅脑与脑深部的 全脑任意区域；还可同步检测化学信号如多巴胺、谷氨酸等神经递质，为区分肿瘤组织与正常组织提供 更全面的依据。"空天院特聘研究骨干、副研究员王蜜霞介绍，这有助于科学开展手术规划，在精准切 除恶性肿瘤的同时，保护大脑运动、语言、认知等功能区。 本次临床试验针对一位胶质瘤患者开展。该患者术前由于脑肿瘤压 ...